Method of Administration. Patients will receive two intradermal injections of approximately 0.5 mL volume on the anterior or medial side of the same thigh. The general area of vaccination will be at a location midway between the inguinal ligament and the knee and will be administered in the same lymph node draining area. The vaccinations will be given every 21 days for 5 doses total. Intradermal vaccinations should be given in a method similar to the “PPD Skin Test” through a 26- or 27-gauge needle (3/8 inch) in the anterior thigh midway between the inguinal ligament and the knee. The whole 1 mL vaccination volume will be administered in 2 different sites approximately 5 cm (about 2 inches) apart from each other, by carefully injecting 500 μL (0.5 cc) at each vaccination site by intradermal injection per the diagram shown below. The vaccinations will be administered using sterile technique by a well-trained research nurse or trained study staff. The patient must be monitored for 1 hour after the vaccination for signs of any adverse reaction. • Cleanse the area by swabbing the skin (an approximately 4 to 5 inch circle) with alcohol pads. • Hold the skin taut before injecting. Place the 2 intradermal vaccinations in 2 quadrants of the cleansed circle. • As depicted below keep the syringe low and flat along the skin surface (inject with needle bevel side up). Inject 500 μL forming a nice “bleb” under the skin. • Slowly retract the needle and allow the “bleb” to resorb. Repeat 1 more time to completely administer the full 1.0 mL volume. Observe the patient and injection sites for 1 hour. • Place a 4x6 sterile gauze bandage over the site on the thigh to protect from irritation for 12 to 24 hours. • Any leakage of the dose onto the skin or inability to deliver the full 1 mL volume to the 2 sites should be noted in the eCRF. • Patients must be observed immediately after vaccinations for signs of an acute allergic reaction. If symptoms such as difficulty breathing, angioedema, diffuse and significant urticaria, and/or hypotension are observed, immediate emergency medical attention will be provided.
Method of Administration. Administrators have the ability to (i) set a Lyft Pass as a one-time or recurring benefit; (ii) set an expiration date and value for each Lyft Pass benefit; and (iii) include time, geofencing, and ride type restrictions.
Method of Administration. The following procedure is recommended for performing the PPD test: 95/102 113 [LOGO] The SILVX xxxdy --------------------------------------------------------------------------------
Method of Administration. The Ceding Company will report to AUL all risks reinsured hereunder by the preparation and submission to AUL of a monthly Statement. The statement shall include, but not be limited to, the information shown in Attachment 1. The Ceding Company may request facultative consideration on any risk written by the Ceding Company on the plans of insurance set out in Exhibit B, by mailing to AUL a Reinsurance Application Form (Attachment 3) properly completed as facultative. Along with reinsurance application, the Ceding Company shall forward copies of its application, medical examination, inspection report, and all other pertinent information. AUL will give the application for reinsurance its prompt consideration and communicate its decision on the risk to the Ceding Company. For risks facultatively reinsured hereunder, the Ceding Company shall also mail to AUL a completed Formal Reinsurance Cession, (Attachment 3), along with copies of all pertinent papers which have not previously been submitted to AUL.
Method of Administration. Budenofalk® 2mg rectal foam can be applied in the morning or evening. The canister is first fitted with an applicator and then shaken for about 15 seconds before the applicator is inserted into the rectum as far as comfortable. Note that the dose is only sufficiently accurate when the pump dome is held downwards as vertically as possible. To administer a dose of Budenofalk® 2mg rectal foam, the pump dome is fully pushed down and very slowly released. Following the activation the applicator should be held in position for 10-15 seconds before being withdrawn from the rectum. The best results are obtained when the intestine is evacuated prior to administration of Budenofalk® 2mg rectal foam.
Method of Administration. Budenofalk® 2mg rectal foam can be applied in the morning or evening. The attending physician determines the duration of use. An acute episode generally subsides after 6 to 8 weeks. Budenofalk® 2mg rectal foam should not be used after this time.
Method of Administration. The capsules containing the gastro-resistant granules should be taken before meals, swallowed whole with plenty of fluid (e.g. a glass of water). The duration of treatment in active Crohn’s Disease and in collagenous colitis should be limited to 8 weeks. The treatment with Budenofalk 3 mg should not be stopped abruptly, but withdrawn gradually (tapering doses). In the first week, the dosage should be reduced to two capsules daily, one in the morning, one in the evening. In the second week, only one capsule should be taken in the morning. Afterwards treatment can be stopped.
Method of Administration. Tacrolimus ointment should be applied as a thin layer to affected areas of the skin and rubbed in gently. Tacrolimus ointment may be used on any part of the body, including xxxx, xxxx and flexure areas, except on mucous membranes. Tacrolimus ointment should not be applied under occlusion (dressings and bandages). Emollients should not be applied to the same area within 2 hours of applying tacrolimus ointment. Contraindications Tacrolimus ointment is contraindicated: • in patients with a known hypersensitivity to the drug, other macrolactams or any of the excipients • in pregnant or breastfeeding women Special Warnings Tacrolimus ointment should not be used in: o congenital or acquired immunodeficiencies o patients on therapies that cause immunosuppression. o potentially malignant or pre-malignant skin lesions. o clinical infections at treatment sites o patients requiring occlusive dressings o patients with Xxxxxxxxx'x syndrome, lamellar ichthyosis, generalized erythroderma or cutaneous Graft Versus Host Disease. Treatment with tacrolimus may be associated with an increased risk of folliculitis and herpes viral infections (herpes simplex dermatitis, herpes simplex, Kaposi's varicelliform eruption). In the presence of these infections, the balance of risks and benefits associated with tacrolimus use should be evaluated. Tacrolimus is extensively metabolised in the liver and although blood concentrations are low following topical therapy, the ointment should be used with caution in patients with hepatic failure. Care should be exercised if applying tacrolimus to patients with extensive skin involvement over an extended period of time, especially in children. Patients with severe atopic dermatitis may have an increased risk of skin bacterial infections (e.g. impetigo) during treatment with tacrolimus ointment. Care should be taken to avoid contact with eyes and mucous membranes. If accidentally applied to these areas, the ointment should be thoroughly wiped off and/or rinsed off with water. As with any topical medicinal product, patients should wash their hands after application if the hands are not intended for treatment. Physicians should advise patients on appropriate sun protection measures, such as minimisation of the time in the sun, use of sunscreen product and covering the skin with appropriate clothing. The use of ultraviolet (UV) light from a solarium, therapy with UVB or UVA in combination with psoralens (PUVA) should be avoided during use of tacrol...
Method of Administration. Oral Contraindications Hypersensitivity to any components of Liothyronine sodium tablets. Patients with angina of effort or cardiovascular diseases and thyrotoxicosis. Special warnings and precautions for use In severe and prolonged hypothyroidism, adrenocortical activity may be decreased. When thyroid replacement therapy is started, metabolism increases more than adrenocortical activity and this can lead to adrenocortical insufficiency requiring supplemental adrenocortical steroids. Liothyronine sodium treatment may result in an increase in insulin or anti-diabetic drug requirements. Care is required for patients with diabetes mellitus and diabetes insipidus. In myxoedema, care must be taken to avoid imposing excessive burden on cardiac muscle affected by prolonged severe thyroid depletion. Care is needed in the elderly. Patients with rare hereditary problems of galactose intolerance, the Xxxx lactase deficiency or glucose-galactose malabsorption should not take this medication. Panhypopituitarism or predisposition to adrenal insufficiency (initiate corticosteroid therapy before starting liothyronine), pregnancy, breast-feeding(see section 4.6 Pregnancy and lactation). A baseline ECG is valuable with initial dosage because changes induced by hypothyroidism can be confused with ischaemia. If metabolism increases too rapidly (causing diarrhoea, nervousness, rapid pulse, insomnia, tremors and sometimes anginal pain where there is latent myocardial ischaemia), reduce dose or withhold for 1-2days and start again at a lower dose. Interaction with other medicinal products and other forms of interaction Liothyronine sodium therapy may potentiate the action of anticoagulants. Phenytoin levels may be increased by liothyronine. Anticonvulsants, such as carbamazepine and phenytoin enhance the metabolism of thyroid hormones and may displace thyroid hormones from plasma proteins. Initiation or discontinuation of anticonvulsant therapy may alter liothyronine dose requirements. If co-administered with cardiac glycosides, adjustment of dosage of cardiac glycoside may be necessary. Colestyramine and colestipol given concurrently reduces gastrointestinal absorption of liothyronine. Liothyronine raises blood sugar levels and this may upset the stability of patients receiving antidiabetic agents. Liothyronine increases receptor sensitivity to catecholamines thus accelerating the response to tricyclic antidepressants. A number of drugs may affect thyroid fu...
Method of Administration. Mektovi is for oral use. The tablets are to be swallowed whole with water. They may be taken with or without food.
